GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 2 808 JPY 0.36% Market Closed
Market Cap: 140.6B JPY
Have any thoughts about
GNI Group Ltd?
Write Note

Operating Margin
GNI Group Ltd

39.7%
Current
20%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
39.7%
=
Operating Profit
9.4B
/
Revenue
23.6B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
JP
GNI Group Ltd
TSE:2160
140.6B JPY
40%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
28%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-22%
Country JP
Market Cap 140.6B JPY
Operating Margin
40%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 320.1B USD
Operating Margin
28%
Country US
Market Cap 147.4B USD
Operating Margin
19%
Country US
Market Cap 119.4B USD
Operating Margin
40%
Country US
Market Cap 113.8B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.4B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.3B EUR
Operating Margin
-22%
No Stocks Found

GNI Group Ltd
Glance View

Market Cap
140.6B JPY
Industry
Biotechnology

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Intrinsic Value
4 123.34 JPY
Undervaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
39.7%
=
Operating Profit
9.4B
/
Revenue
23.6B
What is the Operating Margin of GNI Group Ltd?

Based on GNI Group Ltd's most recent financial statements, the company has Operating Margin of 39.7%.